- Report
- April 2025
- 175 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
Dipivefrin is a medication used to treat glaucoma, a condition in which the pressure inside the eye is too high. It is a prodrug of epinephrine, which works by reducing the amount of fluid in the eye and increasing the outflow of fluid from the eye. It is available as an eye drop and is usually used in combination with other medications. Dipivefrin is a commonly prescribed medication for the treatment of glaucoma and is generally well tolerated. Side effects may include redness, irritation, and dryness of the eyes.
The Dipivefrin market is a subset of the Optical Disorders Drugs market, which includes medications used to treat a variety of eye conditions. This market is highly competitive, with a variety of companies offering products for the treatment of glaucoma. Companies in the Dipivefrin market include Allergan, Bausch + Lomb, Merck, Pfizer, and Santen Pharmaceuticals. Show Less Read more